117 related articles for article (PubMed ID: 15880405)
1. LDL-apheresis improves peripheral arterial occlusive disease with an implication for anti-inflammatory effects.
Kobayashi S; Moriya H; Maesato K; Okamoto K; Ohtake T
J Clin Apher; 2005 Dec; 20(4):239-43. PubMed ID: 15880405
[TBL] [Abstract][Full Text] [Related]
2. LDL-apheresis reduces P-Selectin, CRP and fibrinogen -- possible important implications for improving atherosclerosis.
Kobayashi S; Oka M; Moriya H; Maesato K; Okamoto K; Ohtake T
Ther Apher Dial; 2006 Jun; 10(3):219-23. PubMed ID: 16817784
[TBL] [Abstract][Full Text] [Related]
3. LDL-apheresis up-regulates VEGF and IGF-I in patients with ischemic limb.
Kobayashi S; Moriya H; Negishi K; Maesato K; Ohtake T
J Clin Apher; 2003; 18(3):115-9. PubMed ID: 14569601
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-density lipoprotein apheresis on patients with peripheral arterial disease. Peripheral Arterial Disease LDL Apheresis Multicenter Study (P-LAS).
Tsuchida H; Shigematsu H; Ishimaru S; Iwai T; Akaba N; Umezu S
Int Angiol; 2006 Sep; 25(3):287-92. PubMed ID: 16878078
[TBL] [Abstract][Full Text] [Related]
5. Sustained inhibition of oxidized low-density lipoprotein is involved in the long-term therapeutic effects of apheresis in dialysis patients.
Tsurumi-Ikeya Y; Tamura K; Azuma K; Mitsuhashi H; Wakui H; Nakazawa I; Sugano T; Mochida Y; Ebina T; Hirawa N; Toya Y; Uchino K; Umemura S
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):1058-65. PubMed ID: 20203302
[TBL] [Abstract][Full Text] [Related]
6. Low-density lipoprotein apheresis for haemodialysis patients with peripheral arterial disease reduces reactive oxygen species production via suppression of NADPH oxidase gene expression in leucocytes.
Hara T; Kiyomoto H; Hitomi H; Moriwaki K; Ihara G; Kaifu K; Fujita Y; Higashiyama C; Nishiyama A; Kohno M
Nephrol Dial Transplant; 2009 Dec; 24(12):3818-25. PubMed ID: 19617260
[TBL] [Abstract][Full Text] [Related]
7. Intravenous prostaglandin E1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease.
Matsui K; Ikeda U; Murakami Y; Yoshioka T; Shimada K
Am Heart J; 2003 Feb; 145(2):330-3. PubMed ID: 12595852
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of low-density lipoprotein apheresis in patients with peripheral arterial occlusive disease undergoing hemodialysis treatment.
Morimoto S; Yano Y; Maki K; Sawada K; Iwasaka T
Am J Nephrol; 2007; 27(6):643-8. PubMed ID: 17878713
[TBL] [Abstract][Full Text] [Related]
9. Elevated white blood cell count, CRP and fibrinogen levels are not associated with increased anti-endothelial and anti-ox-LDL antibody, MCP-1, and RANTES levels in early onset occlusive carotid artery disease.
Magyar MT; Bereczki D; Csípo I; Gyimesi E; Csiba L; Valikovics A; Balla J; Sipka S
Cytokine; 2007 Jan; 37(1):44-50. PubMed ID: 17382553
[TBL] [Abstract][Full Text] [Related]
10. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study.
McDermott MM; Guralnik JM; Corsi A; Albay M; Macchi C; Bandinelli S; Ferrucci L
Am Heart J; 2005 Aug; 150(2):276-81. PubMed ID: 16086930
[TBL] [Abstract][Full Text] [Related]
11. Blood flow analysis of the head and lower limbs by the laser Doppler blood flowmeter during LDL apheresis.
Ebihara I; Sato T; Hirayama K; Seki M; Enami T; Kawahara H; Niwayama J; Miyahara T; Shibata M; Maeda N; Kurosawa T; Yamagata K; Sanaka T
Ther Apher Dial; 2007 Oct; 11(5):325-30. PubMed ID: 17845391
[TBL] [Abstract][Full Text] [Related]
12. Effects of two whole blood systems (DALI and Liposorber D) for LDL apheresis on lipids and cardiovascular risk markers in severe hypercholesterolemia.
Otto C; Berster J; Otto B; Parhofer KG
J Clin Apher; 2007; 22(6):301-5. PubMed ID: 17935245
[TBL] [Abstract][Full Text] [Related]
13. Effect of different LDL-apheresis methods on parameters involved in atherosclerosis.
Hershcovici T; Schechner V; Orlin J; Harell D; Beigel Y
J Clin Apher; 2004; 19(2):90-7. PubMed ID: 15274202
[TBL] [Abstract][Full Text] [Related]
14. The effect of low-dose atorvastatin on circulating monocyte chemoattractant protein-1 in patients with type 2 diabetes complicated by hyperlipidemia.
Takebayashi K; Matsumoto S; Wakabayashi S; Inukai Y; Matsutomo R; Aso Y; Inukai T
Metabolism; 2005 Sep; 54(9):1225-9. PubMed ID: 16125534
[TBL] [Abstract][Full Text] [Related]
15. Changes in myocardial vasoreactivity after drastic reduction of plasma fibrinogen and cholesterol: a clinical study in long-term heart transplant survivors using positron emission tomography.
Jaeger BR; Bengel FM; Odaka K; Uberfuhr P; Labarrere CA; Bengsch S; Engelschalk C; Kreuzer E; Reichart B; Schwaiger M; Seidel D
J Heart Lung Transplant; 2005 Dec; 24(12):2022-30. PubMed ID: 16364844
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen apheresis in the treatment of peripheral arterial disease.
Ramunni A; Brescia P; Quaranta D; Plantamura M; Ria R; Coratelli P
Blood Purif; 2007; 25(5-6):404-10. PubMed ID: 17901692
[TBL] [Abstract][Full Text] [Related]
17. Effects of selective LDL apheresis on plasma concentrations of ICAM-1, VCAM-1 and P-selectin in diabetic patients with arteriosclerosis obliterans and receiving maintenance hemodialysis.
Utsumi K; Kawabe M; Hirama A; Ueda K; Kamada Y; Arii K; Komaba Y; Katsura K; Iino Y; Katayama Y
Clin Chim Acta; 2007 Feb; 377(1-2):198-200. PubMed ID: 17126824
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-density lipoprotein apheresis on inflammatory and noninflammatory high-density lipoprotein cholesterol.
Opole IO; Belmont JM; Kumar A; Moriarty PM
Am J Cardiol; 2007 Nov; 100(9):1416-8. PubMed ID: 17950800
[TBL] [Abstract][Full Text] [Related]
19. IL-18 is involved in vascular injury in end-stage renal disease patients.
Porazko T; Kúzniar J; Kusztal M; Kúzniar TJ; Weyde W; Kuriata-Kordek M; Klinger M
Nephrol Dial Transplant; 2009 Feb; 24(2):589-96. PubMed ID: 18775894
[TBL] [Abstract][Full Text] [Related]
20. Influence of fibrinogen and hematocrit on the early outcome of angioplasty in patients with PAOD.
Rudofsky G; Strubel G; Michler E; Kuegler C; Biro F
J Endovasc Ther; 2004 Apr; 11(2):125-31. PubMed ID: 15056033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
